Quick Read – Viking Therapeutics (VKTX) is the most closely watched biotech acquisition target. – A buyer such as Eli Lilly (LLY) would benefit, as would Viking shareholders, and at least one GLP-1 competitor. – The analyst who called NVIDIA in 2010 just named his top 10 stocks…
d Viking Therapeutics wasn’t one of them. Get them here FREE
Polymarket traders are watching one biotech more closely than any other for an acquisition. Viking Therapeutics (NASDAQ: VKTX) carries a 38.5% implied probability of being acquired before 2027, with all-time volume above $1.68 million on that single contract. The hook is obesity.
Viking’s VK2735 dual GLP-1/GIP agonist is arguably the most advanced obesity asset not yet owned by Big Pharma. This scenario analysis examines who would actually benefit if a deal happens. Why Viking Is the Most-Watched M&A Target Viking is a clinical-stage biotech with no revenue and a market cap near $3.59 billion.